enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Drop in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 4,663 shares, a drop of 90.4% from the August 15th total of 48,573 shares. Based on an average trading volume of 13,212 shares, the short-interest ratio is currently 0.4 days.

enGene Stock Performance

ENGNW stock remained flat at $0.23 on Thursday. enGene has a fifty-two week low of $0.11 and a fifty-two week high of $4.20. The firm has a 50 day moving average of $0.29 and a 200 day moving average of $1.08.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.